Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019524 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
A Phase 1 study, sponsored by COL George Peoples, MD, FACS.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02019524: Completed Phase 1 study, sponsored by COL George Peoples, MD, FACS.
NCT02019524 is a Phase 1 study that has completed, run by COL George Peoples, MD, FACS. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02019524, a Phase 1 study, has completed, sponsored by COL George Peoples, MD, FACS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a single-center, randomized, single-blinded, three-arm phase Ib study of the folate binding protein vaccines E39 and J65. The study target population are patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. Disease-free subjects after standard of care multi-modality therapy will be screened and HLA typed. E39 and J65 are cytotoxic T-lymphocyte-eliciting peptide vaccines that are restricted to HLA-A2+ patients (approximately 50% of the U.S. population).
Interventions
- BIOLOGICAL E39 peptide vaccine
- BIOLOGICAL E39 vaccine then J65 vaccine
- BIOLOGICAL J65 vaccine then E39 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-09-30 |
| Est. Completion | 2016-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019524
The ClinicalTrials.gov registry entry for NCT02019524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COL George Peoples, MD, FACS, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which E39 peptide vaccine is the first listed.
NCT02019524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019524 about?
NCT02019524 is a clinical study titled "Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients". This is a single-center, randomized, single-blinded, three-arm phase Ib study of the folate binding protein vaccines E39 and J65. The study target population are patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. Disease-free subjects after st...
What is the current status of trial NCT02019524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2013-09-30. Estimated completion is 2016-12-06.
What interventions are being tested in trial NCT02019524?
The interventions under investigation include: E39 peptide vaccine (BIOLOGICAL), E39 vaccine then J65 vaccine (BIOLOGICAL), J65 vaccine then E39 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02019524?
This trial is sponsored by COL George Peoples, MD, FACS, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.